Yüklüyor......
Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer
On 13 June 2018, Genentech, Inc. issued a press release announcing that the US FDA had approved the antiangiogenesis drug, bevacizumab, in combination with chemotherapy for frontline and maintenance therapy for women with newly diagnosed ovarian cancer. Regulatory approval was based on the National...
Kaydedildi:
| Yayımlandı: | Future Oncol |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Future Medicine Ltd
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7036749/ https://ncbi.nlm.nih.gov/pubmed/31746224 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2019-0042 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|